Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted (NASDAQ:MNPR)

Group 1 - Monopar Therapeutics Inc. has experienced a significant surge in its stock price over the past year, moving from a market cap under $9 million to a more favorable position following its acquisition of the Wilson disease candidate ALXN-1840 [1] - The company had cash reserves of $7.1 million prior to the surge, indicating a previously precarious financial situation [1] Group 2 - The Busted IPO Forum, led by Bret Jensen, focuses on small-cap stocks that have been public for 18 months to 6 years and are trading significantly below their offering price [1]